新辅助纳武利尤单抗治疗高危非转移性肾细胞癌
本研究为早期临床试验,纳入17例高危非转移性肾细胞癌患者,术前接受三剂纳武利尤单抗(每2周一次)后手术。任意级别不良事件发生率为82.4%,3级事件为11.8%,无4-5级事件;所有可评估患者影像学均为疾病稳定,1例(6.7%)出现免疫相关病理缓解。2年无转移生存率和总生存率分别为85.1%和100%。
要点
- 新辅助纳武利尤单抗未延迟手术,安全性可接受。
- 影像学客观缓解率低,但部分患者出现免疫相关病理缓解。
- 术后生活质量稳定,≥6个月时较基线改善。
核心结论
- 高危非转移性肾细胞癌患者术前接受三剂纳武利尤单抗安全可行,未延迟手术。
- 影像学缓解率低,但部分患者可观察到免疫相关病理缓解。
研究设计与样本
- 早期临床试验,纳入17例非转移性高危肾细胞癌患者。
- 术前每2周给予纳武利尤单抗共三剂,随后手术。
主要发现
- 任意级别不良事件发生14例(82.4%),3级事件2例(11.8%)。
- 10例(58.8%)发生可能归因于纳武利尤单抗的不良事件,均为1-2级。
- 无4-5级不良事件发生。
- 最常见不良事件为1级乏力(41.2%)、1级瘙痒(29.4%)和1级皮疹(29.4%)。
- 所有可评估患者影像学为疾病稳定,1例(6.7%)出现免疫相关病理缓解特征。
临床怎么用
- 对于高危非转移性肾细胞癌,新辅助纳武利尤单抗可作为安全可行的探索性治疗选择。
- 治疗期间需监测免疫相关不良事件,但严重事件发生率较低。
局限性
- 样本量小(17例),为早期临床试验。
- 未报告随机对照或长期随访数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neoadjuvant immune checkpoint blockade represents a novel approach for potentially decreasing the risk of recurrence in patients with nonmetastatic renal cell carcinoma (RCC). In this early phase clincal tiral, we evaluated the safety and tolerability of neoadjuvant treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab in patients with nonmetastatic high-risk RCC. Nonprimary endpoints included objective radiographic tumor response rate, immune-related pathologic response rate, quality of life alterations, and metastasis-free and overall survival. In total, 17 patients were enrolled in this study and underwent surgery without a delay after receiving three every-2-wk doses of neoadjuvant nivolumab. Adverse events (AEs) of any grade occurred in 14 (82.4%) patients, with two (11.8%) experiencing grade 3 events. Ten (58.8%) patients experienced an AE of any grade potentially attributable to nivolumab (all grade 1-2), and no grade 4-5 AEs occurred regardless of treatment attribution. The most common AEs were grade 1 fatigue (41.2%), grade 1 pruritis (29.4%), and grade 1 rash (29.4%). All evaluable patients had stable disease as per established radiographic criteria, with one (6.7%) demonstrating features of an immune-related pathologic response. Quality of life remained stable during treatment, with improvements relative to baseline noted at ≥6 mo postoperatively. Metastasis-free survival and overall survival were 85.1% and 100% at 2 yr, respectively. PATIENT SUMMARY: In this study, we evaluated the safety and tolerability of preoperative administration of three doses of the immune checkpoint inhibitor nivolumab in patients with clinically localized high-risk renal cell carcinoma. We demonstrated the safety of this approach and found that, although most patients will not experience a radiographic response to treatment, a subset may have features of an immune-related pathologic response.
引用
- Gorin MA, Patel HD, Rowe SP, et al. Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. Eur Urol Oncol. 2021. PMID: 34049847. doi:10.1016/j.euo.2021.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。